Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America
Authors:
- Mauricio SalvoMSMauricio Salvo
- Evelin González-FeliúEGEvelin González-Feliú
- Jessica ToroJTJessica Toro
- Iván GallegosIGIván Gallegos
- Ignacio MaureiraIMIgnacio Maureira
- Nicolás Miranda-GonzálezNMNicolás Miranda-González
- Olga BarajasOBOlga Barajas
- Eva BustamanteEBEva Bustamante
- Mónica AhumadaMAMónica Ahumada
- Alicia ColomboACAlicia Colombo
- Ricardo ArmisénRicardo Armisén
- Camilo VillamánCVCamilo Villamán
Open Access
- 8 September 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (9) , 899
Abstract
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries. To overcome some of these barriers, we have designed a 25-gene panel that contains predictive biomarkers for most current and near-future available therapies in Chile and Latin America. Library preparation was optimized to account for low DNA integrity observed in formalin-fixed paraffin-embedded tissue. The workflow includes an automated bioinformatic pipeline that accounts for the underrepresentation of Latin Americans in genome databases. The panel detected small insertions, deletions, and single nucleotide variants down to allelic frequencies of 0.05 with high sensitivity, specificity, and reproducibility. The workflow was validated in 272 clinical samples from several solid tumor types, including gallbladder (GBC). More than 50 biomarkers were detected in these samples, mainly in BRCA1/2, KRAS, and PIK3CA genes. In GBC, biomarkers for PARP, EGFR, PIK3CA, mTOR, and Hedgehog signaling inhibitors were found. Thus, this small NGS panel is an accurate and sensitive method that may constitute a more cost-efficient alternative to multiple non-NGS assays and costly, large NGS panels. This kind of streamlined assay with automated bioinformatics analysis may facilitate the implementation of precision medicine in Latin America.Keywords
All Related Versions
Funding Information
- Consejo Nacional para Investigaciones Científicas y Tecnológicas (FONDEF IDEA IT16I10051, FONDECYT 1171463, FONDEF D10E1007 , D11I1029)
- Horizon 2020 (825741)
- Universidad de Chile (VID INFRAESTRUCTURA 0440/2018, VID U-Redes 704/2016)
This publication has 36 references indexed in Scilit:
- VarDict: a novel and versatile variant caller for next-generation sequencing in cancer researchNucleic Acids Research, 2016
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- An ensemble approach to accurately detect somatic mutations using SomaticSeqGenome Biology, 2015
- Next generation sequencing in cancer research and clinical applicationBiological Procedures Online, 2013
- LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasetsNucleic Acids Research, 2012
- Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairsBioinformatics, 2012
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingGenome Research, 2012
- Genomics for the worldNature, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010